With an orthopedic business split on the horizon, Johnson & Johnson has seen steady growth and momentum in that segment, leaders said in a first-quarter earnings call.
Johnson & Johnson saw growth across all areas of its orthopedic division, according to its first-quarter financial results.
“The orthopedics business, under the leadership of Hani Abouhalka, delivered a strong first quarter with encouraging momentum across key platforms,” CFO Joseph Wolk said, as transcribed by investing.com. “We are continuing to make targeted investments in the business and working towards a mid-2027 separation.”
New product launches were a major driver for the U.S. orthopedics business, Darren Snellgrove, vice president of investor relations said in the call.
Movement is also continuing with Johnson & Johnson’s planned separation of its orthopedic business, which will operate as DePuy Synthes.
“We look forward to sharing further updates later this year, and as stated last October, we are evaluating all separation vehicles that create shareholder value and set up the DePuy Synthes business for long-term success,” Mr. Wolk said.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
